Cowen Prime Services LLC Sells 239,352 Shares of NeoGenomics, Inc. (NEO)
Cowen Prime Services LLC reduced its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 18.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,069,374 shares of the medical research company’s stock after selling 239,352 shares during the period. NeoGenomics comprises approximately 5.7% of Cowen Prime Services LLC’s portfolio, making the stock its 3rd biggest holding. Cowen Prime Services LLC owned about 1.35% of NeoGenomics worth $11,902,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of NeoGenomics in the second quarter worth approximately $20,651,000. Falcon Point Capital LLC grew its holdings in shares of NeoGenomics by 338.6% in the second quarter. Falcon Point Capital LLC now owns 1,100,474 shares of the medical research company’s stock worth $9,860,000 after purchasing an additional 849,589 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of NeoGenomics by 66.1% in the second quarter. Russell Investments Group Ltd. now owns 1,996,710 shares of the medical research company’s stock worth $17,891,000 after purchasing an additional 794,281 shares during the last quarter. Granite Investment Partners LLC grew its holdings in shares of NeoGenomics by 52.4% in the second quarter. Granite Investment Partners LLC now owns 1,976,020 shares of the medical research company’s stock worth $17,706,000 after purchasing an additional 679,778 shares during the last quarter. Finally, Northpointe Capital LLC grew its holdings in shares of NeoGenomics by 91.8% in the second quarter. Northpointe Capital LLC now owns 927,008 shares of the medical research company’s stock worth $8,306,000 after purchasing an additional 443,710 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.
Shares of NeoGenomics, Inc. (NASDAQ NEO) traded up $0.12 during mid-day trading on Thursday, reaching $9.13. The company had a trading volume of 247,700 shares, compared to its average volume of 347,311. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. The stock has a market capitalization of $724.49, a price-to-earnings ratio of 180.20, a price-to-earnings-growth ratio of 8.58 and a beta of 0.84. NeoGenomics, Inc. has a 12 month low of $7.12 and a 12 month high of $11.63.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The business had revenue of $63.05 million during the quarter, compared to analyst estimates of $63.11 million. NeoGenomics had a positive return on equity of 3.97% and a negative net margin of 4.78%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.04 earnings per share. research analysts predict that NeoGenomics, Inc. will post 0.05 EPS for the current year.
NEO has been the topic of several recent analyst reports. BidaskClub cut shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Gabelli started coverage on shares of NeoGenomics in a report on Thursday, August 24th. They issued a “buy” rating and a $9.00 target price on the stock. Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Thursday, October 26th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Finally, ValuEngine raised NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.33.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.